Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Review clinical classifications, diagnostic procedures, and management strategies for cardiomyopathy and heart failure in this comprehensive overview.

Updates to national guidelines for the management of hypertrophic cardiomyopathy (HCM) endorse cardiac myosin inhibitor use in certain cases, greenlight more intensive physical activity, and expand ...

Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is contraindicated with ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, currently we have three FDA approved ...

Nonischemic cardiomyopathy is when problems with your heart muscle aren’t due to reduced blood flow. Instead, causes include genetics, infections, and autoimmune conditions. Cardiomyopathy is the ...

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...